Those with pancreatic adenocarcinoma and a personal history of another cancer associated with hereditary breast and ovarian cancer or Lynch syndrome may be more likely to carry germline mutations.
Researchers conducted a review of more than 400 patients with hormone receptor-positive breast cancer to determine if high Oncotype DX RS is associated with a greater likelihood the cancer is hereditary.
Adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy provides significant survival benefit for patients with AML and a FLT3 mutation.
A combination treatment of mitogen-activated protein kinase MEK inhibitor and chemotherapy did not improve progression-free survival in patients with advanced lung cancer caused by a KRAS gene mutation.
Presence of JAK2 mutation and leukocytosis are strong predictors for thromboembolic events in patients with essential thrombocythemia (ET).
Genetic signatures similar to BRCA1/BRCA2 mutations could make PARP inhibition a treatment option for some breast cancers.
Given the frequency of gene mutations in patients with early-onset CRC, genetic counseling and testing could be considered for this population.
Variants of the MC1R gene, associated with red hair, pale skin, and freckles, increases the number of genetic mutations related to skin cancer and the level of other gene mutations, further increasing the risk for skin cancer.
Genetic mutations affecting the immune system were identified in patients who develop more than one CRC tumor at the same time, and understanding how these cancers develop could improve therapy targeting.
Researchers say it's likely that all the major genetic mutations related to colorectal cancer have been discovered.
The drug denosumab, which blocks a bone gene, may also prevent breast cancer caused by a BRCA1 mutation. This already approved drug could be available quickly, and would be the first drug for breast cancer prevention.
The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.
Binimetinib may represent a new effective therapy for patients with NRAS-mutant melanoma, both before and after immunotherapy. That is the conclusion of the phase 3 NEMO study, results of which were presented at the ASCO 2016 Annual Meeting.
Palbociclib Plus Fulvestrant Provides Significant Benefit in Hormone Receptor-Positive Metastatic Breast CancerJune 03, 2016
ESR1 mutations detected in plasma circulating tumor DNA were identified in a high percentage of patients with hormone receptor-positive metastatic breast cancer, confirming an important role in endocrine resistance, according to an analysis of data from the phase 3 PALOMA-3 reported at the 2016 ASCO Annual Meeting.
ESR1 Mutations Predict Worse Outcome in HR-positive Metastatic Breast Cancer Treated with Aromatase InhibitorsJune 03, 2016
The presence of circulating ESR1 somatic mutations at disease progression in patients with HR-positive metastatic breast cancer treated with first-line AIs represent a strong and independent poor prognostic value for overall survival but no predictive value, a study presented at the 2016 ASCO Annual Meeting has found.
Plasma from a blood draw can be used to test for BRAF V600 mutations in advanced cancers in just 90 minutes, and results were comparable to using tissue biopsy.
The 2016 consensus statement from the International Association for the Study of Lung Cancer (IASLC) describes how to best manage EGFR-mutation-positive NSCLC.
Disparities in BRCA1/2 testing in black and white women is attributable to differences in physician recommendations, according to a recent study.
Progression-free and Overall Survival Better With Mutations Affecting DNA Repair Genes in Ovarian CancerApril 08, 2016
Women with advanced ovarian cancer who had mutations affecting DNA repair genes had longer progression-free and overall survival than women without the mutations.
Germline mutations to the RECQL gene were identified in 0.5% of patients with familial breast cancer in a Chinese population.
A pattern of mutations across several key cancer genes was found in patients with throat cancer who were exposed to both human papillomavirus (HPV) and tobacco smoke.
Among 1915 patients with ovarian cancer, almost 1 in 5 had inherited mutations in genes associated with risk of ovarian cancer. Furthermore, a total of 11 genes are now suspected of causing hereditary ovarian cancer.
Two distinct causes of HER2 activation in lung cancer were demonstrated in a recent study. These findings imply that HER2-positive lung cancer may need different targeted therapies to combat these related but possibly distinct diseases.
The researchers found that nearly one fifth of women with ovarian cancer carried mutations in genes that were associated with ovarian cancer risk beyond the BRCA1 and BRCA2 genes.
The evolution of drug resistance in a patient with lung cancer was demonstrated in a recent case. In the case, molecular analysis of a metastatic lesion revealed resistance to a third targeted therapy; however, the new mutation restored tumor response to the first targeted therapy used.
Comprehensive genomic screening may be warranted for all pediatric patients with cancer, not just those with a family history of cancer, according to results of a detailed analysis of germline mutations in cancer predisposition genes.
Spliceosomal-mutant leukemias displayed greater sensitivity to pharmacologic modulation of splicing than their wildtype counterparts.
Most patients with NSCLC that has metastasized to the brain have a dire prognosis. However, researchers have identified a subset of those patients who have a rare genetic mutation and are living significantly longer than patients without the mutation.
By analyzing the types of gut bacteria present around colorectal tumors, researchers have found a way to predict key genetic mutations in the tumors themselves, a method that could eventually inform the development of colorectal cancer diagnostics and therapeutics.
Researchers identified two new cancer-causing gene mutations that could lead to more targeted and effective treatments for certain lung and prostate cancers.
Sign Up for Free e-newsletters
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
- In Older Women With Breast Cancer QoL May Predict 10-Year Mortality
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Chronic Opioid Use Observed in More Than 50% of Oropharynx Cancer Cases
- Support for Exercise Programs During, After Cancer Treatment
- Oncology Clinicians Disagree on School Attendance for Children With Cancer
- False-Positive Cancer Screening Results May Increase Likelihood of Future Screenings
- Lenalidomide Alone or With Dexamethasone Effective in Relapsed Multiple Myeloma
- Chronic Opioid Use Observed in More Than 50% of Oropharynx Cancer Cases
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|